• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

GLP-1RAs in patients with psoriasis.

作者信息

Paschou Ioanna A, Sali Evangelia, Paschou Stavroula A, Psaltopoulou Theodora, Nicolaidou Electra, Stratigos Alexander J

机构信息

1st Department of Dermatology and Venereology, "Andreas Sygros" Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Endocrine Unit and Diabetes Centre, Department of Clinical Therapeutics, School of Medicine, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.

出版信息

Hormones (Athens). 2025 Feb 20. doi: 10.1007/s42000-025-00635-5.

DOI:10.1007/s42000-025-00635-5
PMID:39971882
Abstract
摘要

相似文献

1
GLP-1RAs in patients with psoriasis.银屑病患者中的胰高血糖素样肽-1受体激动剂
Hormones (Athens). 2025 Feb 20. doi: 10.1007/s42000-025-00635-5.
2
Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.胰高血糖素样肽-1受体激动剂对2型糖尿病血糖控制、体重和血脂水平的比较疗效：系统评价和网状Meta分析
BMJ. 2024 Jan 29;384:e076410. doi: 10.1136/bmj-2023-076410.
3
Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.长效胰高血糖素样肽-1 受体激动剂与艾塞那肽每日 2 次和西格列汀在 2 型糖尿病中的疗效和安全性比较：系统评价和荟萃分析。
Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5.
4
Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary Disease Exacerbations in Patients With Type 2 Diabetes.降糖药物与2型糖尿病患者慢性阻塞性肺疾病急性加重风险
JAMA Intern Med. 2025 Apr 1;185(4):399-410. doi: 10.1001/jamainternmed.2024.7811.
5
GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias.用于2型糖尿病及阿尔茨海默病和相关痴呆症的胰高糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂药物
JAMA Neurol. 2025 May 1;82(5):439-449. doi: 10.1001/jamaneurol.2025.0353.
6
Effects of glucagon-like peptide-1 receptor agonists on major coronary events in patients with type 2 diabetes.胰高血糖素样肽-1受体激动剂对2型糖尿病患者主要冠脉事件的影响。
Diabetes Obes Metab. 2023 Apr;25 Suppl 1:53-63. doi: 10.1111/dom.15043. Epub 2023 Mar 31.
7
GLP-1RA vs DPP-4i Use and Rates of Hyperkalemia and RAS Blockade Discontinuation in Type 2 Diabetes.GLP-1RA 与 DPP-4i 的使用与 2 型糖尿病高钾血症和 RAS 阻滞剂停药率的关系。
JAMA Intern Med. 2024 Oct 1;184(10):1195-1203. doi: 10.1001/jamainternmed.2024.3806.
8
Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes.胰高血糖素样肽 1 受体激动剂与 2 型糖尿病患者的 13 种肥胖相关癌症。
JAMA Netw Open. 2024 Jul 1;7(7):e2421305. doi: 10.1001/jamanetworkopen.2024.21305.
9
Glucagon-Like Peptide-1 Receptor Agonists and Incidence of Dementia Among Older Adults With Type 2 Diabetes : A Target Trial Emulation.胰高血糖素样肽-1受体激动剂与2型糖尿病老年人痴呆症发病率：一项目标试验模拟研究
Ann Intern Med. 2025 Jul 22. doi: 10.7326/ANNALS-24-02648.
10
Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study.使用胰高血糖素样肽-1受体激动剂的2型糖尿病成人患者的营养缺乏与肌肉流失：一项回顾性观察研究。
Obes Pillars. 2025 Jun 10;15:100186. doi: 10.1016/j.obpill.2025.100186. eCollection 2025 Sep.

引用本文的文献

1
GLP-1 agonists on a roll: from obesity to psoriasis - an elixir to watch!胰高血糖素样肽-1激动剂正崭露头角：从肥胖症到牛皮癣——一种值得关注的灵丹妙药！
Hormones (Athens). 2025 Jul 23. doi: 10.1007/s42000-025-00697-5.
2
GLP-1RA and the possible skin aging.胰高血糖素样肽-1受体激动剂与可能的皮肤衰老。
Endocrine. 2025 Jun 11. doi: 10.1007/s12020-025-04293-w.

本文引用的文献

1
GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach.GLP-1 受体激动剂治疗肥胖症：一种有前途的方法。
Front Endocrinol (Lausanne). 2023 Feb 1;14:1085799. doi: 10.3389/fendo.2023.1085799. eCollection 2023.
2
Advances in the pathogenesis of psoriasis: from keratinocyte perspective.银屑病发病机制的研究进展：从角质形成细胞角度看。
Cell Death Dis. 2022 Jan 24;13(1):81. doi: 10.1038/s41419-022-04523-3.
3
Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial.
利拉鲁肽治疗 2 型糖尿病合并银屑病患者的随机对照试验：胰高血糖素样肽-1 受体激动剂。
J Dermatolog Treat. 2022 May;33(3):1428-1434. doi: 10.1080/09546634.2020.1826392. Epub 2020 Sep 24.
4
Psoriasis Pathogenesis and Treatment.银屑病发病机制与治疗。
Int J Mol Sci. 2019 Mar 23;20(6):1475. doi: 10.3390/ijms20061475.
5
Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study.利拉鲁肽（一种胰高血糖素样肽-1 类似物）治疗可有效改善 2 型糖尿病合并银屑病患者的皮肤损伤：一项前瞻性队列研究。
Diabetes Res Clin Pract. 2019 Apr;150:167-173. doi: 10.1016/j.diabres.2019.03.002. Epub 2019 Mar 4.
6
Psoriasis and the risk of diabetes: A prospective population-based cohort study.银屑病与糖尿病风险：一项基于人群的前瞻性队列研究。
J Am Acad Dermatol. 2018 Feb;78(2):315-322.e1. doi: 10.1016/j.jaad.2017.10.050. Epub 2017 Nov 8.
7
Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis.胰高血糖素样肽-1 受体激动剂对银屑病患者的影响。
Ther Adv Endocrinol Metab. 2014 Apr;5(2):34-8. doi: 10.1177/2042018814543483.
8
Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial.胰高血糖素样肽-1受体激动剂利拉鲁肽对糖耐量正常患者银屑病无效——一项随机安慰剂对照试验
J Eur Acad Dermatol Venereol. 2015 Mar;29(3):555-9. doi: 10.1111/jdv.12629. Epub 2014 Aug 20.
9
Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: a prospective case-series study.在 2 型糖尿病中，胰高血糖素样肽-1 类似物治疗期间银屑病的改善与真皮 γδ T 细胞数量的减少有关：一项前瞻性病例系列研究。
Br J Dermatol. 2014 Jul;171(1):155-61. doi: 10.1111/bjd.12886. Epub 2014 Jul 16.
10
Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques.在银屑病斑块中，胰高血糖素样肽-1 受体的表达增加。
Exp Dermatol. 2013 Feb;22(2):150-2. doi: 10.1111/exd.12081.